Traders bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading on Thursday. $201.32 million flowed into the stock on the tick-up and $92.94 million flowed out of the stock on the tick-down, for a money net flow of $108.38 million into the stock. Of all companies tracked, Pfizer had the 9th highest net in-flow for the day. Pfizer traded down ($0.08) for the day and closed at $34.80

A number of brokerages have commented on PFE. Argus restated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research report on Sunday, August 28th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Friday, May 6th. Morgan Stanley restated a “hold” rating and issued a $36.00 price target on shares of Pfizer in a research report on Tuesday, May 17th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target for the company in a research report on Monday, June 27th. Finally, Berenberg Bank began coverage on Pfizer in a research report on Thursday, May 12th. They issued a “hold” rating and a $38.00 price target for the company. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $38.82.

The company has a market capitalization of $210.90 billion and a price-to-earnings ratio of 30.82. The stock’s 50 day moving average is $35.63 and its 200-day moving average is $33.45.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter in the prior year, the firm earned $0.56 EPS. Pfizer’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post $2.46 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 1st. Investors of record on Friday, August 5th were paid a $0.30 dividend. The ex-dividend date was Wednesday, August 3rd. This represents a $1.20 annualized dividend and a dividend yield of 3.45%.

A number of large investors have recently bought and sold shares of PFE. CAM Group Holding A S raised its stake in Pfizer by 111.2% in the fourth quarter. CAM Group Holding A S now owns 1,148,915 shares of the biopharmaceutical company’s stock valued at $37,087,000 after buying an additional 605,000 shares during the period. Advantus Capital Management Inc raised its stake in Pfizer by 2.9% in the fourth quarter. Advantus Capital Management Inc now owns 595,182 shares of the biopharmaceutical company’s stock valued at $19,212,000 after buying an additional 16,618 shares during the period. Wellington Shields & Co. LLC raised its stake in Pfizer by 17.4% in the fourth quarter. Wellington Shields & Co. LLC now owns 52,579 shares of the biopharmaceutical company’s stock valued at $1,697,000 after buying an additional 7,809 shares during the period. Afam Capital Inc. raised its stake in Pfizer by 5.9% in the fourth quarter. Afam Capital Inc. now owns 76,884 shares of the biopharmaceutical company’s stock valued at $2,482,000 after buying an additional 4,295 shares during the period. Finally, Mutual of America Capital Management LLC raised its stake in Pfizer by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 794,289 shares of the biopharmaceutical company’s stock valued at $25,640,000 after buying an additional 3,766 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.